Stock Events

Stock Events

PTC Therapeutics 

$69.30
16
-$2.10-2.94% Friday 20:00
+$0.00+0%Friday 20:00After hours

Statistics

Day High
69.39
Day Low
69.3
52W High
90.87
52W Low
56.51
Volume
37,812
Avg. Volume
-
Mkt Cap
5.78B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

22OctExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-1.67
2.23
6.14
10.04
Expected EPS
0.275576
Actual EPS
N/A

Financials

39.44%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.73BRevenue
682.64MNet Income

Analyst Ratings

104.13Average Price Target
The highest estimate is 130.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
88%
Hold
13%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PTCT. It's not an investment recommendation.
NVIDIA
7
NVDA
Apple
6
AAPL
Microsoft
6
MSFT
Amazon
6
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for rare diseases, directly competing with PTC Therapeutics' gene therapy and RNA-based treatments.
Biogen
BIIB
Mkt Cap32.28B
Biogen develops and markets therapies for neurological and neurodegenerative diseases, overlapping with PTC Therapeutics' focus on rare diseases and conditions.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is involved in creating treatments for cystic fibrosis and other serious diseases, competing with PTC Therapeutics in the rare disease drug market.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals specializes in RNA interference (RNAi) therapies, offering a competitive technology platform to PTC Therapeutics' RNA-based treatments.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals is a leader in RNA-targeted drug discovery and development, making it a direct competitor to PTC Therapeutics in the RNA therapy space.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other drugs for rare genetic diseases, competing with PTC Therapeutics in the rare disease market.
Ultragenyx Pharmaceutical
RARE
Mkt Cap2.52B
Ultragenyx Pharmaceutical develops therapies for rare and ultra-rare diseases, including gene therapies, competing in the same niche as PTC Therapeutics.
Novartis
NVS
Mkt Cap292.35B
Novartis offers a broad range of healthcare products, including treatments for rare diseases through its gene therapy division, competing with PTC Therapeutics on multiple fronts.

About

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Show more...
CEO
Matthew Klein
Employees
991
Country
United States
ISIN
US69366J2006
WKN
000A1W0MW

Listings

MU
DE
BH3.MU
XETRA
DE
BH3.XETRA
STU
DE
BH3.STU
F
DE
BH3.F

0 Comments

Share your thoughts

FAQ

What is PTC Therapeutics stock price today?▼
The current price of PTCT is $69.30 USD — it has decreased by -2.94% in the past 24 hours. Watch PTC Therapeutics stock price performance more closely on the chart.
What is PTC Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange PTC Therapeutics stocks are traded under the ticker PTCT.
Is PTC Therapeutics stock price growing?▼
PTCT stock has fallen by -1.13% compared to the previous week, the month change is a +0.13% rise, over the last year PTC Therapeutics has showed a +21.03% increase.
What is PTC Therapeutics market cap?▼
Today PTC Therapeutics has the market capitalization of 5.78B
When is the next PTC Therapeutics earnings date?▼
PTC Therapeutics is going to release the next earnings report on October 22, 2026.
What were PTC Therapeutics earnings last quarter?▼
PTCT earnings for the last quarter are 0.92 USD per share, whereas the estimation was 0.24 USD resulting in a +289.32% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is PTC Therapeutics revenue for the last year?▼
PTC Therapeutics revenue for the last year amounts to 1.73B USD.
What is PTC Therapeutics net income for the last year?▼
PTCT net income for the last year is 682.64M USD.
How many employees does PTC Therapeutics have?▼
As of September 05, 2026, the company has 991 employees.
In which sector is PTC Therapeutics located?▼
PTC Therapeutics operates in the Health & Wellness sector.
When did PTC Therapeutics complete a stock split?▼
PTC Therapeutics has not had any recent stock splits.
Where is PTC Therapeutics headquartered?▼
PTC Therapeutics is headquartered in WARREN, United States.